Drug Information

Drug (ID: DG01320) and It's Reported Resistant Information

• Name: Abatacept
• Indication:
  In total 1 Indication(s)
  Rheumatoid arthritis [ICD-11: FA20]; Approved; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Validated by in-vivo Model for This Drug (1 diseases)
  Autoimmune disease [ICD-11: 4A4Z]; [2]
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Immune dysregulation syndrome [ICD-11: 4A01]; [1]
• Target: Activation B7-1 antigen (CD80); CD80_HUMAN; [1]
• Target: T-lymphocyte activation antigen CD86 (FUN1); CD86_HUMAN; [1]
• TTD Drug ID: D0EW4L
• DrugBank ID: DB01281

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-04: Immune system diseases

Autoimmune disease [ICD-11: 4A4Z]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Aldehyde dehydrogenase 1A1 (ALDH1A1) [2]

• Resistant Disease: Autoimmune disease [ICD-11: 4A4Z.0]
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vivo Model: Th17-mediated EAD model; Mus musculus
• Experiment for Molecule Alteration: qRT-PCR
• Mechanism Description: Abatacept-resistant memory Th17 cells exhibit genes for aldehyde dehydrogenases. Memory-phenotype pTh17 cells exhibit a unique metabolic pathway that may involve ALDH for both survival and function.

References

• Ref 1: Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency .J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2790-2800.e15. doi: 10.1016/j.jaip.2019.06.011. Epub 2019 Jun 22. 10.1016/j.jaip.2019.06.011
• Ref 2: Targeting abatacept-resistant T-helper-17 cells by aldehyde dehydrogenase inhibition. iScience. 2023 Dec 9;27(1):108646.